GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Neuphoria Therapeutics Inc.
The stock price of Bionomics, a biotech company focused on treating anxiety disorders, reflects the potential of its lead drug. Its price trajectory is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Neuro
Neuphoria Therapeutics, affiliated with Bionomics, develops drugs to treat central nervous system disorders such as anxiety disorders and post-traumatic stress disorder. We've categorized it under "Neurology," and the chart below shows the company's performance in the mental health sector.
Broad Market Index - GURU.Markets
Bionomics is an Australian biopharmaceutical company developing drugs to treat central nervous system disorders such as anxiety disorders and PTSD. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market.
Change in the price of a company, segment, and market as a whole per day
NEUP - Daily change in the company's share price Neuphoria Therapeutics Inc.
For Neuphoria Therapeutics Inc., which develops drugs for neurological disorders, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Neuro
Neuphoria Therapeutics Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with NEUP, which focuses on CNS diseases, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Neuphoria Therapeutics is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the overall stock market's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Neuphoria Therapeutics Inc.
The year-over-year performance of Neuphoria Therapeutics Inc., which operates under the Bionomics brand, is a story of drug development for treating central nervous system diseases. Its 12-month market cap is entirely dependent on clinical trial data for its lead candidate for the treatment of post-traumatic stress disorder (PTSD), a huge unmet need.
Annual dynamics of market capitalization of the market segment - Neuro
Bionomics, a clinical-stage biotech company, develops drugs for the treatment of neurological disorders. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Neuphoria Therapeutics (Bionomics) is a biotech company focused on CNS disorders. Its stock is a bet on the success of a specific drug in its portfolio. Its performance chart, compared to the market, shows how investor expectations for its developments outweigh general economic factors, creating a trajectory entirely dependent on news from the lab.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Neuphoria Therapeutics Inc.
Neuphoria (formerly Bionomics) is a clinical-stage biotech focused on CNS disorders. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its anxiety disorder drug is generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Neuro
This chart reflects the dynamics of the volatile biotech sector. For Neuphoria (Bionomics), a clinical-stage company, it's the backdrop. Its movements illustrate how investor expectations surrounding the results of its CNS drug trials are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Neuphoria Therapeutics (formerly Bionomics) is an Australian biotech company developing drugs to treat central nervous system disorders, such as anxiety. Its value is determined by progress in clinical trials. The overall market chart provides only background, while Neuphoria's performance is driven by development news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Neuphoria Therapeutics Inc.
Neuphoria Therapeutics, which develops therapies for central nervous system (CNS) disorders, is experiencing high volatility. Its weekly stock price is reflecting a sharp reaction to news about clinical trials of its drugs, particularly in complex areas such as anxiety disorders and depression.
Weekly dynamics of market capitalization of the market segment - Neuro
Neuphoria operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire segment. The chart will show whether NEUP is moving with the industry or whether its drug development successes are creating a story of their own.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Neuphoria Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how NEUP shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
NEUP - Market capitalization of the company Neuphoria Therapeutics Inc.
The chart of Neuphoria Therapeutics (formerly Bionomics) tells the story of the search for new drugs to treat anxiety disorders and PTSD. The company's market capitalization reflects investor expectations for its drugs. Its volatility reflects the market's assessment of its clinical data and the enormous need for more effective treatments.
NEUP - Share of the company's market capitalization Neuphoria Therapeutics Inc. within the market segment - Neuro
Neuphoria Therapeutics, affiliated with Bionomics, develops drugs to treat central nervous system disorders. Its stake in the sector will be based on the potential of its scientific developments. The chart shows how investors view its pipeline of candidates for anxiety disorders and other neurological conditions.
Market capitalization of the market segment - Neuro
Neuphoria Therapeutics (formerly Bionomics) develops drugs to treat central nervous system disorders, including anxiety disorders. The chart below shows the market capitalization of the neuroscience sector, reflecting the company's focus on finding new solutions to improve mental health.
Market capitalization of all companies included in a broad market index - GURU.Markets
Neuphoria is a biopharmaceutical company developing drugs to treat neurological diseases. Its market capitalization reflects the potential of its research in this complex field. The chart below shows the economic weight of companies at the forefront of neuroscience.
Book value capitalization of the company, segment and market as a whole
NEUP - Book value capitalization of the company Neuphoria Therapeutics Inc.
Neuphoria Therapeutics' foundation is capital for developing drugs for CNS disorders. The company's book value, formerly known as Bionomics, consists of the intellectual property for its drug candidates and funds for their clinical trials. The chart below shows how the company uses its financial resources to discover new treatments.
NEUP - Share of the company's book capitalization Neuphoria Therapeutics Inc. within the market segment - Neuro
Neuphoria Therapeutics, which develops drugs for the central nervous system, has key assets in the form of R&D laboratories. The S_BCap_Seg graph shows its share of scientific infrastructure, reflecting its focus on neuroscience research.
Market segment balance sheet capitalization - Neuro
Neuphoria Therapeutics (formerly Bionomics) is a biotech company developing drugs to treat central nervous system disorders. Its primary asset is intellectual property. This chart shows how "light" its balance sheet is, with value driven by scientific research rather than production assets.
Book value of all companies included in the broad market index - GURU.Markets
Neuphoria's balance sheet represents scientific capital for the treatment of CNS disorders. The company's assets include the rights to develop its drug candidates and the financial resources to conduct clinical trials. This is the material base aimed at creating new treatments for anxiety disorders, depression, and post-traumatic stress disorder.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (Bionomics) is a biotechnology company focused on diseases of the central nervous system. Its book value is cash. Its market capitalization reflects the market valuation of its lead drug candidate for the treatment of post-traumatic stress disorder and other anxiety disorders.
Market to book capitalization ratio in a market segment - Neuro
Neuphoria Therapeutics develops drugs to treat diseases of the central nervous system. It is a clinical-stage biotech. The chart shows how the market values the potential of its lead candidate, placing a premium on its book value, which primarily reflects its available cash.
Market to book capitalization ratio for the market as a whole
Neuphoria Therapeutics (formerly Bionomics) develops drugs to treat diseases of the central nervous system. The company's value depends almost entirely on the success of its clinical trials. The chart demonstrates how market valuation reflects investors' faith in science and future cash flows, rather than current tangible assets.
Debts of the company, segment and market as a whole
NEUP - Company debts Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics), a biotech company focused on CNS diseases, is using debt to fund its clinical trials. This chart shows the company's capital raising for the development of drugs to treat post-traumatic stress disorder and other anxiety disorders.
Market segment debts - Neuro
Neuphoria Therapeutics (formerly Bionomics) is a biotech company focused on CNS disorders, particularly post-traumatic stress disorder. After years of development, the company is in late-stage clinical trials. This chart shows its financial position at this crucial stage, which will determine its future.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) develops drugs to treat diseases of the central nervous system. This chart shows its reliance on debt. In psychiatry and neurology, where clinical trials are complex and lengthy, high debt levels can create significant pressure on a company even before results are available.
Market segment debt to market segment book capitalization - Neuro
Neuphoria Therapeutics (formerly Bionomics) is a biotech company focused on central nervous system diseases, such as anxiety disorders. This chart for the biotech sector shows how the industry as a whole attracts capital to fund lengthy and expensive research. It provides context for assessing the company's financial strength.
Debt to book value of all companies in the market
Neuphoria Therapeutics, affiliated with Bionomics, develops drugs to treat central nervous system disorders. This chart, which reflects the overall debt-to-book value ratio of the market, is important for understanding the investment climate in biotech. Capital availability determines a company's ability to finance expensive and lengthy clinical trials.
P/E of the company, segment and market as a whole
P/E - Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) is a biotech company developing drugs to treat central nervous system disorders, such as anxiety disorders and PTSD. This chart reflects the urgent need for new treatments for mental health disorders. Its significance demonstrates investor confidence in the potential of its drug candidates.
P/E of the market segment - Neuro
Neuphoria Therapeutics, like other biotechs, operates in a sector with high expectations. This chart shows the average P/E for this industry. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its CNS treatments compared to the average prospects of other biotech companies.
P/E of the market as a whole
Neuphoria Therapeutics (formerly Bionomics) is an Australian biotech company developing drugs to treat central nervous system disorders such as anxiety disorders and PTSD. This chart shows sentiment in the biotech sector. The company's valuation depends on the success of its clinical programs in the highly challenging field of psychiatry.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders and PTSD. The chart reflects future revenue expectations, which are contingent on the success of clinical trials of its lead candidates.
%20P%2FE%20Neuphoria%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Neuphoria-Therapeutics-Inc.&v=1772648219336 "Chart of the company's future (projected) P/E Neuphoria Therapeutics Inc.")
Future (projected) P/E of the market segment - Neuro
Neuphoria Therapeutics (formerly Bionomics) is a clinical-stage company developing drugs for the treatment of central nervous system disorders, including anxiety disorders and PTSD. This chart displays its future profitability expectations, allowing us to assess how the market perceives its scientific developments in psychiatry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772648219362 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Neuphoria Therapeutics (formerly Bionomics) is a biotech company developing drugs to treat central nervous system disorders. Its valuation is based on expectations of clinical trial success. In line with overall market forecasts, Neuphoria is driven by regulatory announcements and laboratory data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772648219377 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system (CNS) disorders, including anxiety disorders and PTSD. Its financial metrics reflect R&D expenditures. This chart illustrates investments in the development of new treatments for mental disorders.
Profit of companies in the market segment - Neuro
Neuphoria Therapeutics (formerly Bionomics) is a clinical-stage biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders and post-traumatic stress disorder. This chart shows the profitability of the neuroscience segment. Its clinical trial successes could lead to new treatment standards.
Overall market profit
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders. Its success depends on the results of clinical trials. This chart shows general market cycles, while the company's stock is driven by lab news and the potential of its developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, such as anxiety disorders and PTSD. This chart reflects analysts' expectations for future earnings, which depend on the success of clinical trials and potential partnerships with major pharmaceutical companies.
%20profit%20of%20the%20company%20Neuphoria%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Neuphoria-Therapeutics-Inc.&v=1772648219535 "Graph of future (projected) profit of the company Neuphoria Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Neuphoria Therapeutics Inc. is a biopharmaceutical company developing new treatments for central nervous system disorders. This chart shows revenue projections for the neuroscience sector. It reflects expectations for advances in understanding and treating complex psychiatric and neurological diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772648219575 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Neuphoria Therapeutics (formerly Bionomics) develops drugs for the treatment of central nervous system diseases. For a biotech company, the market's profit forecast is an indicator of investment appetite. The expected growth seen in the chart suggests that investors will be more willing to fund risky but promising clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772648219617 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. At the clinical stage, P/S is not a key metric. Its valuation depends on trial results and the potential market size for its future drugs.
P/S market segment - Neuro
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders and post-traumatic stress disorder. This chart shows how the market views the potential of their leading drug candidates and future revenue streams in this complex field.
P/S of the market as a whole
Neuphoria Therapeutics (formerly Bionomics) is a biotech company developing drugs to treat diseases of the central nervous system. It has no revenue, and its valuation reflects the potential of its clinical programs. This chart, based on actual revenue, highlights that the company's valuation is a bet on success in brain drug development.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Neuphoria Therapeutics Inc.
Neuphoria Therapeutics is likely the successor to Bionomics and is focused on developing drugs for diseases of the central nervous system. This chart reflects investor expectations for future revenue from its neuroscience developments, betting on the success of its clinical programs in this complex therapeutic area.
%20P%2FS%20Neuphoria%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Neuphoria-Therapeutics-Inc.&v=1772648219748 "The graph of the company's future (projected) P/S Neuphoria Therapeutics Inc.")
Future (projected) P/S of the market segment - Neuro
Neuphoria Therapeutics Inc., formerly Bionomics, is a clinical-stage biopharmaceutical company developing new treatments for central nervous system disorders, such as anxiety and post-traumatic stress disorder. This chart shows how the market perceives the future commercial potential of its drugs, comparing it to other companies in the neuroscience sector.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772648219768 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs to treat central nervous system disorders, including anxiety disorders and PTSD. This chart shows overall market revenue expectations, and NEUP illustrates how the overwhelming need for effective treatments for mental disorders is driving investment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772648219805 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system (CNS) disorders, such as anxiety and depressive disorders. The company currently has no commercial products, so its revenue in this chart is derived from royalties rather than sales.
Sales of companies in the market segment - Neuro
Neuphoria Therapeutics is likely a biotech company focused on neuroscience. At this stage, its revenue, if any, may be derived from partnerships. This chart allows investors to estimate the financial flows supporting its research on the path to commercialization.
Overall market sales
Neuphoria Therapeutics (affiliated with Bionomics) is a biotech company developing drugs to treat central nervous system disorders. The need for such drugs is enormous and unaffected by the economic climate. This timeline is irrelevant to the company, whose success is determined solely by clinical trial results and regulatory approval.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders. Its revenue forecast is dependent on the success of clinical trials. This chart reflects analyst expectations for its neuroscience pipeline.
%20sales%20of%20the%20company%20Neuphoria%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Neuphoria-Therapeutics-Inc.&v=1772648219963 "Schedule of future (projected) sales of the company Neuphoria Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Neuro
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. This chart shows projected revenue for the entire neuroscience segment. It allows one to assess the growth potential of this market, which is important for the commercialization of the company's drug portfolio.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772648220002 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. Its success depends on the results of clinical trials. This graph of overall market expectations reflects the investment climate. A positive environment facilitates raising the capital needed to fund R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772648220032 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs to treat diseases of the central nervous system. This chart reflects the company's current status in clinical development. It shows the extent of its investment in research, the success of which determines its future.
Market segment marginality - Neuro
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing new drugs to treat serious central nervous system disorders, such as anxiety and PTSD. This chart shows the average profitability in the neuroscience sector. It provides context for understanding the potential commercial success of the company's drug portfolio in this challenging market.
Market marginality as a whole
Neuphoria Therapeutics Inc. is likely a biopharmaceutical company focused on treating neurological or psychiatric disorders. This graph of overall market profitability doesn't reflect the specifics of its business, which depends on years of expensive research and the ability to solve complex medical problems.
Employees in the company, segment and market as a whole
Number of employees in the company Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (formerly Bionomics) is a clinical-stage biopharmaceutical company focused on diseases of the central nervous system. Its compact team manages the development of promising drugs. This chart shows the size of the focused group of experts leading expensive clinical trials in one of the most complex areas of medicine.
Share of the company's employees Neuphoria Therapeutics Inc. within the market segment - Neuro
Neuphoria Therapeutics, operating through its subsidiary Bionomics, is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. This chart illustrates its scientific focus. It reflects the proportion of neuroscientists and researchers working on new treatments for anxiety disorders and post-traumatic stress disorder within the company.
Number of employees in the market segment - Neuro
Neuphoria Therapeutics, formerly Bionomics, develops drugs to treat central nervous system disorders. This chart illustrates its neuroscience workforce. The growing number of scientists in this field indicates a high demand for new, more effective treatments for anxiety disorders and PTSD, a key area for the company.
Number of employees in the market as a whole
Neuphoria Therapeutics Inc., formerly known as Bionomics, develops drugs to treat diseases of the central nervous system. Mental health and neuroscience are priority areas in modern medicine. This graph shows overall employment, and advances in this area are important for society and the economy as a whole, which is reflected in company growth.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics is a biotech company focused on neuroscience. Its market valuation reflects its faith in its scientific approach. This chart shows the enormous value investors place on each scientist working on treating brain diseases. It's a premium on intellectual capital, pure and simple.
%20of%20the%20company%20Neuphoria%20Therapeutics%20Inc.%20(NEUP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Neuphoria-Therapeutics-Inc.-NEUP&v=1772648220393 "Chart of market capitalization per employee (in thousands of dollars) of the company Neuphoria Therapeutics Inc. (NEUP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Neuphoria Therapeutics (formerly Bionomics) develops drugs for the treatment of central nervous system diseases. Its market capitalization per employee reflects the market valuation of its pipeline of drug candidates. A comparison with other neuroscience biotechs shows how promising investors view its research pipeline.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772648220442 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders. This chart reflects how the market views the company's scientific pipeline and its team's potential to create new, effective treatments for millions of people.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772648220462 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Neuphoria Therapeutics Inc. (NEUP)
Neuphoria (Bionomics) is a biotech company developing drugs to treat central nervous system disorders, primarily anxiety disorders and PTSD. It's an R&D company. This chart, in negative territory, shows how much capital is being burned for each employee seeking new solutions in the complex field of psychiatry.
%20Chart%20Neuphoria%20Therapeutics%20Inc.%20(NEUP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Neuphoria-Therapeutics-Inc.-NEUP&v=1772648220493 "Company Profit Per Employee (in thousands of dollars) Chart Neuphoria Therapeutics Inc. (NEUP)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Neuphoria Therapeutics, formerly Bionomics, is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as anxiety disorders and PTSD. This chart illustrates the potential value of their developments. It shows the potential profitability of a successful drug developed by a small team of scientists for the vast neurological market.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772648220535 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Neuphoria Therapeutics (formerly Bionomics) is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, such as anxiety disorders and PTSD. At the clinical development stage, this chart shows the R&D investment per employee required to complete the expensive phases of clinical trials for new drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772648220552 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics (formerly Bionomics) is a biotechnology company developing drugs for the central nervous system. During clinical trials, this graph does not reflect commercial activity. It represents investment in research. Success in development will lead to a sharp increase in this indicator after the product's launch.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Neuphoria-Therapeutics-Inc.-NEUP&v=1772648220566 "Sales chart per company employee Neuphoria Therapeutics Inc. (NEUP)")
Sales per employee in the market segment - Neuro
Neuphoria Therapeutics (NEUP) is likely related to Bionomics, which specializes in treating CNS disorders (anxiety, PTSD). This chart shows the average revenue per employee in the pharmaceutical segment. For an R&D-stage company like NEUP/Bionomics, comparison to this benchmark (zero) highlights their focus on developing drugs for complex neurological conditions.
Sales per employee for the market as a whole
Neuphoria Therapeutics (NEUP) is a biotech company (formerly Bionomics) focused on CNS diseases. It is a clinical-stage R&D company. There is no revenue from drug sales (license fees may be involved). This metric does not reflect operational efficiency. Attention is focused on the results of their drug trials.
Short shares by company, segment and market as a whole
Shares shorted by company Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics (formerly Bionomics) is a biotech company developing drugs for the treatment of central nervous system disorders, particularly anxiety disorders. This chart shows the odds against their development. Bears believe their drug candidates will fail to prove effective in clinical trials, a common problem for anxiety medications.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Neuphoria-Therapeutics-Inc.-NEUP&v=1772648220655 "Short Shares Chart for the Company Neuphoria Therapeutics Inc. (NEUP)")
Shares shorted by market segment - Neuro
Neuphoria (NEUP) / Bionomics is a biotech company developing drugs for anxiety and PTSD. It's a challenging market dominated by generics. This chart shows the pessimism in the neuroscience sector. The surge in shorts across the sector is a bet that new CNS drugs will fail in trials or be uncompetitive on price. Investors are doubtful of the commercial success of the entire industry.
Shares shorted by the overall market
Neuphoria (NEUP) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing NEUP won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics (affiliated with Bionomics) is a biotech company focused on treating central nervous system disorders. Like many in the sector, its "pulse" is volatile. This chart shows how investor interest can remain "cool" for a long time during research, then suddenly "overheat" on news of a partnership or successful clinical trial.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Neuphoria-Therapeutics-Inc.-NEUP&v=1772648220770 "RSI 14 indicator chart for the company's stock Neuphoria Therapeutics Inc. (NEUP)")
RSI 14 Market Segment - Neuro
Neuphoria (via Bionomics) is a biotech company focused on developing new treatments for severe CNS disorders, such as PTSD and anxiety disorders. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Neuphoria compares to that.
RSI 14 for the overall market
Neuphoria (NEUP) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NEUP (Neuphoria Therapeutics Inc.)
Neuphoria Therapeutics (formerly Bionomics) is a biotech company focused on developing drugs for the treatment of central nervous system disorders, particularly anxiety disorders and PTSD. This chart shows the speculative average 12-month price target from analysts based on their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NEUP-Neuphoria-Therapeutics-Inc.&v=1772648220950 "A chart showing analyst consensus forecasts for the expected stock price. NEUP (Neuphoria Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price NEUP (Neuphoria Therapeutics Inc.)
Neuphoria (Bionomics) is a biotech company developing a new class of drugs (BNC210) for the treatment of anxiety disorders. This chart shows the difference between the market valuation and the consensus estimate. It highlights the potential experts see in this non-benzodiazepine approach to anxiety treatment.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NEUP-Neuphoria-Therapeutics-Inc.&v=1772648220974 "A chart showing the difference between the consensus forecast and the actual stock price. NEUP (Neuphoria Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Neuphoria (Bionomics) is a biotech company focused on treating central nervous system disorders such as anxiety and PTSD. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe breakthroughs in treating mental and neurological disorders are possible or whether they consider the sector too risky.
Analysts' consensus forecast for the overall market share price
Neuphoria Therapeutics (formerly Bionomics) is an Australian biotech company specializing in the development of drugs for the treatment of central nervous system disorders (anxiety, PTSD). This chart shows the overall market "risk appetite." For Neuphoria, which operates in the complex field of psychiatry, overall market optimism is critical for raising capital for long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Neuphoria Therapeutics Inc.
Neuphoria (Bionomics) is a clinical-stage biotech company focused on neuroscience. They are developing drugs (targeting the alpha-7 receptor) for the treatment of cognitive disorders (schizophrenia, Alzheimer's). This graph is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Neuro
Neuphoria Therapeutics (NEUP), likely related to Bionomics, is a biopharmaceutical company focused on neuroscience, possibly developing drugs for anxiety or PTSD. The chart shows the average index for the segment, helping investors assess how this company compares to the average risk in the neuroscience sector.
The AKIM Index for the overall market
Neuphoria Therapeutics (formerly Bionomics) is a biotech company developing drugs to treat anxiety disorders and PTSD (BNC210). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is seeking a partner or acquisition, stacks up against overall economic trends.
